FierzW. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends. Med Sci Monitor2004;10RA111–23.
2.
Price Waterhouse Coopers. Personalized medicine:the emerging pharmacogenomics revolution. Price Waterhouse Coopers, Global Technology Center, Health Research Institute, February2005.
3.
HunsbergerS, RubinsteinLV, DanceyJ, KornEL. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med2005;24:2171–81.
4.
AroraA, ScholarEM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther2005;315:971–9.
5.
DaviesNM, JamaliF. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter. J Pharmacy Pharm Sci2004;7:332–6.
6.
ComisRL. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer. Oncologist2005;10:467–70.
7.
DanceyJE. Predictive factors for epidermal growth factor receptor inhibitors—the bull's-eye hits the arrow. Cancer Cell2004;5:411–5.
8.
Department of Health and Human Services. 130th National Cancer Advisory Board Minutes, June2–3, 2004.
